Precision Optics is transforming from a niche engineering supplier to a large manufacturer. If management executes effectively. This transition could drive outsized earnings growth and a higher stock price.
The recent $10M public stock offer at $3.60 was oversubscribed. Investors included existing shareholders and new value institutional investors. Further, the CEO, CFO, COO, and directors bought shares in the recent offering at the same terms as outside investors.
Now the question for investors. Can POCI transform from a thinly traded microcap into a small med tech growth company?
The transformation is becoming more visible when looking at the prior 3 quarters. Q1 2026 revenue was 6.70M, Q2 2026 was 7.4 M, and the most recent reported Q3 2026 was 8.70M. Gross margins also had a major recovery, from 14.40% in Q1, 2.80% in Q2, and 24% in the most recent Q3 2026. Adjusted EBITDA went from negative to positive in Q3 2026.
Risks:
Execution remains the largest risk and is discussed during conference calls. Management highlighted low yields, scrap costs, labor inefficiencies, and training challenges. Gross margins fell to 2.8% in Q2, and EBITDA guidance shifted from a projected profit to a meaningful loss. This suggests management underestimated the difficulty of scaling.
Customer concentration remains significant. A large portion of revenue depends on a small number of customers. During Q3, an aerospace customer requested a temporary production slowdown. This shows how results can change if a key customer delays or reduces orders. While recent financing has improved liquidity, dilution risk has not disappeared. And capital may be needed if profitability takes longer than expected. POCI is a small manufacturer. It is struggling to prove it can convert revenue growth into sustainable earnings
Opportunities:
Precision Optics is transitioning from a small engineering company to a production manufacturer. Potentially creating attractive operating leverage.
Management stated that we are operating at a record level on the latest Q3 2026 conference call. This was evident as revenue increased from $6.7 million in Q1, $7.4 million in Q2, and to a record $8.7 million in Q3 2026.
POCI's aerospace business may be a valuable hidden asset. Its satellite-related programs generate roughly $3.6 million in quarterly revenue. And production yields are improving to 97%. This implies an annual revenue run rate of $14-15 million for a single customer. In addition to aerospace, the company supports attractive medical markets. Such as cystoscopes, ophthalmic devices, arthroscopy, urology, and otoscopy. Management says these segments are growing at mid to high-teen annual rates. Furthermore, medical products create sticky customer relationships. Because of their long product life cycles and regulatory barriers. Also, the recent $10 million financing reduces near term financial risk.
Valuation Metrics:
Comparison to Peers
POCI = 52 Week price change = 6.43%,current ratio = 2.10, book value 2.10, revenue per share = 3.10,quarterly revenue growth (yoy) = 108.00%
Management's technical background and shareholder alignment provide a foundation as the company moves from a niche engineering business into a larger manufacturing operation. From 2006 to 2011, the CEO was the company's Executive Vice President and Chief Scientific Officer. He earned a PhD in Applied Physics from Princeton University, and he holds an MA in Mechanical/Aerospace Engineering. He's an optical and imaging guy, so his background makes sense.
I started with a long position in POCI. POCI is a high risk idea. But I would recommend POCI as a speculative investment.
